Application of a nanoimmunoassay platform to assess changes in EGFR-dependent signaling pathways in lung cancer cell line: surgical resections and laser-capture microdissection from patient-derived tumor cells exposed to EGFR tyrosine kinase inhibitors

To fully enable the vision of 'bench-bedside' requires the development of not only novel therapies, but novel techniques for evaluating their efficacy in cell lines, animal models and primary tumor material. This report describes our development of a technique employing a nanoimmunoassay platform for the analysis of signaling protein activation in primary non-small lunch cancer (NSCLC) solid tumors.